Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.


Updates from The Motley Fool

Latest updates on Novo Nordisk from Fool.com.  The Fool has written over 200 articles on Novo Nordisk.
Top Diabetes Stocks to Buy Today

More people than ever are being diagnosed with diabetes, and big advances in treatment could make...



Stock Performance

View Interactive NVO Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novo Nordisk.
Current Price: $50.44
Prev Close: $49.81
Open: $50.16
Bid: $48.50
Ask: $50.70
Day's Range: $50.11 - $50.63
52wk Range: $41.03 - $58.37
Volume: 1,378,900
Avg Vol 1,677,885
Market Cap: $124B
P/E (ttm): 0.00
EPS (ttm): $0.00
Div & Yield: $0.95 (1.8%)

Company Rating

What our community thinks about Novo Nordisk.
CAPS Rating 5 out of 5
 
725 Outperform
26 Underperform
CAPS All Stars
 
176 Outperform
6 Underperform

How do you think Novo Nordisk will perform against the market?



You pick for Novo Nordisk is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Lars Fruergaard Jørgensen, CEO

94% Approve

Based on 122 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novo Nordisk.

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

  • Exchange: NYSE
  • Sector: Healthcare
  • Industry: Drug Makers